Anixa Biosciences (NASDAQ:ANIX) Trading 12.1% Higher

Anixa Biosciences, Inc. (NASDAQ:ANIXGet Rating)’s stock price rose 12.1% during mid-day trading on Monday . The stock traded as high as $4.76 and last traded at $4.55. Approximately 211,321 shares traded hands during trading, an increase of 162% from the average daily volume of 80,621 shares. The stock had previously closed at $4.06.

Anixa Biosciences Trading Down 4.9 %

The company has a fifty day simple moving average of $3.37 and a 200 day simple moving average of $3.12.

Anixa Biosciences (NASDAQ:ANIXGet Rating) last posted its quarterly earnings data on Friday, June 10th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. Equities analysts anticipate that Anixa Biosciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently bought and sold shares of the company. US Bancorp DE grew its holdings in Anixa Biosciences by 3,312.3% during the 1st quarter. US Bancorp DE now owns 13,649 shares of the company’s stock worth $37,000 after acquiring an additional 13,249 shares during the period. Keybank National Association OH acquired a new stake in Anixa Biosciences during the first quarter worth approximately $42,000. Virtu Financial LLC bought a new stake in Anixa Biosciences in the second quarter worth approximately $45,000. B. Riley Wealth Management Inc. boosted its holdings in shares of Anixa Biosciences by 41.7% during the 4th quarter. B. Riley Wealth Management Inc. now owns 17,000 shares of the company’s stock worth $50,000 after buying an additional 5,000 shares in the last quarter. Finally, Tyler Stone Wealth Management acquired a new stake in shares of Anixa Biosciences during the 4th quarter worth approximately $62,000. Institutional investors own 11.38% of the company’s stock.

About Anixa Biosciences

(Get Rating)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

Featured Stories

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with's FREE daily email newsletter.